DRKS00022305已完成未知
Evaluation of the Patient-Doctor-Relationship during the COVID-19 pandemia
Klinik für Allgemeine Orthopädie und Tumororthopädie, Universitätsklinikum Münster0 个研究点目标入组 285 人开始时间: 2020年7月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 285
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- All
入选标准
- •All patients with an appointment in our outpatient clinic.
排除标准
- •deafness, blindness, dementia, insurmountable language barrier
研究者
相似试验
招募中
不适用
Evaluation of the effect of clinician-patient relationship protocol on vital signs controlEmergency endodontic diseases.Diseases of pulp and periapical tissuesIRCT20150318021507N2Vice Chancellor For research,Shahid Sadoughi University of Medical Scieces60
尚未招募
不适用
The influence of patient-clinician interaction context on acupuncture outcomes in functional dyspepsiaKCT0002229Kyung Hee University Oriental Medical Center59
Unknown
不适用
doctor-patient-relationshipAnalysing the vision and opinion of opinionleaders on how the doctor-patient relation is meaningfull for the complex care for MUS patients. More specific how the opinionleader -out of his vision, his conceptual modell- takes part in this relationship and possibly uses the relationship as a powerful and important tool to care/treat the patients with chronical MUS.NL-OMON26443Cooperation between Maastricht University CAPHRI and Atrium-Orbis MedicalCenter15
尚未招募
1 期
Impact of doctor-patient participation in medical decision-making model on acupuncture combined with medicine for hearing rehabilitation in patients with sudden deafnessITMCTR2000003476Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
已完成
不适用
Involving medical companions in an explanation about switching to a biosimilar.Patients taking biologic medications (e.g. adalimumab, etanercept, infliximab, rituximab, tocilizumab) for rheumatic diseases.Patients taking biologic medications (e.g. adalimumab, etanercept, infliximab, rituximab, tocilizumab) for dermatological diseases.Decision makingInflammatory and Immune System - Rheumatoid arthritisSkin - Dermatological conditionsPublic Health - Health service researchACTRN12619001435178Professor Keith Petrie79